JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

JNJ

234.45

+2.23%↑

ISRG

484.22

-3.03%↓

ABT

108.56

-0.91%↓

RDY

13.74

+2.16%↑

NEOG

10.4

-0.38%↓

Home・Stock List・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Open

SectorHealthcare

Buy Sell

Overview

Share price change

24h

Current

Min

Max

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-0.05% downside

News Sentiment

By Acuity

50%

147 / 352 Healthcare

Mirati Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Feb 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 Feb 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 Feb 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 Feb 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 Feb 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 Feb 2026, 23:23 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 Feb 2026, 22:57 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 Feb 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 Feb 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 Feb 2026, 21:51 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 Feb 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 Feb 2026, 21:49 UTC

Earnings

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 Feb 2026, 21:39 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 Feb 2026, 21:36 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 Feb 2026, 21:34 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 Feb 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 Feb 2026, 21:23 UTC

Earnings

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 Feb 2026, 21:19 UTC

Earnings

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 Feb 2026, 21:17 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 Feb 2026, 21:17 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 Feb 2026, 21:10 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 Feb 2026, 21:08 UTC

Earnings

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 Feb 2026, 21:07 UTC

Earnings

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 Feb 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Net $608.7M >PLTR

2 Feb 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Rev $1.41B >PLTR

2 Feb 2026, 21:05 UTC

Earnings

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 Feb 2026, 21:05 UTC

Earnings

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 Feb 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 Feb 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q EPS 24c >PLTR

2 Feb 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer Comparison

Price change

Mirati Therapeutics Inc Forecast

Price Target

By TipRanks

-0.05% downside

12 Months Forecast

Average 58.67 USD -0.05%

High 59 USD

Low 58 USD

Based on 5 Wall Street analysts offering 12 month price targets forMirati Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Mirati Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

147 / 352 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.